Novavax, Inc. (NASDAQ: NVAX) announced today that it has successfully completed a pre-clinical safety and efficacy study of its RSV ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE